178 related articles for article (PubMed ID: 24139926)
21. Antimicrobial therapy and control of multidrug-resistant Pseudomonas aeruginosa bacteremia in a teaching hospital in Taiwan.
Leung CH; Wang NY; Liu CP; Weng LC; Hsieh FC; Lee CM
J Microbiol Immunol Infect; 2008 Dec; 41(6):491-8. PubMed ID: 19255693
[TBL] [Abstract][Full Text] [Related]
22. Osteoarticular infection caused by MDR Pseudomonas aeruginosa: the benefits of combination therapy with colistin plus β-lactams.
Ribera A; Benavent E; Lora-Tamayo J; Tubau F; Pedrero S; Cabo X; Ariza J; Murillo O
J Antimicrob Chemother; 2015 Dec; 70(12):3357-65. PubMed ID: 26419763
[TBL] [Abstract][Full Text] [Related]
23. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection.
Lodise TP; Patel N; Kwa A; Graves J; Furuno JP; Graffunder E; Lomaestro B; McGregor JC
Antimicrob Agents Chemother; 2007 Oct; 51(10):3510-5. PubMed ID: 17646415
[TBL] [Abstract][Full Text] [Related]
24. [Pseudomonas aeruginosa: combined treatment vs. monotherapy].
Bodí M; Garnacho J
Med Intensiva; 2007 Mar; 31(2):83-7. PubMed ID: 17433186
[TBL] [Abstract][Full Text] [Related]
25. Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas aeruginosa bacteremia.
Bliziotis IA; Petrosillo N; Michalopoulos A; Samonis G; Falagas ME
PLoS One; 2011; 6(10):e26470. PubMed ID: 22046290
[TBL] [Abstract][Full Text] [Related]
26. A novel combination regimen for the treatment of refractory bacteremia due to multidrug-resistant Pseudomonas aeruginosa in a liver transplant recipient.
Sun HY; Shields RK; Cacciarelli TV; Muder RR; Singh N
Transpl Infect Dis; 2010 Dec; 12(6):555-60. PubMed ID: 20626709
[TBL] [Abstract][Full Text] [Related]
27. Inappropriate initial antimicrobial therapy as a risk factor for mortality in patients with community-onset Pseudomonas aeruginosa bacteraemia.
Cheong HS; Kang CI; Wi YM; Ko KS; Chung DR; Lee NY; Song JH; Peck KR
Eur J Clin Microbiol Infect Dis; 2008 Dec; 27(12):1219-25. PubMed ID: 18575908
[TBL] [Abstract][Full Text] [Related]
28. Risk factors for pan-resistant Pseudomonas aeruginosa bacteremia and the adequacy of antibiotic therapy.
Tuon FF; Gortz LW; Rocha JL
Braz J Infect Dis; 2012; 16(4):351-6. PubMed ID: 22846123
[TBL] [Abstract][Full Text] [Related]
29. Impact of AmpC overexpression on outcomes of patients with Pseudomonas aeruginosa bacteremia.
Tam VH; Chang KT; Schilling AN; LaRocco MT; Genty LO; Garey KW
Diagn Microbiol Infect Dis; 2009 Mar; 63(3):279-85. PubMed ID: 19135330
[TBL] [Abstract][Full Text] [Related]
30. Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa.
Rossolini GM; Mantengoli E
Clin Microbiol Infect; 2005 Jul; 11 Suppl 4():17-32. PubMed ID: 15953020
[TBL] [Abstract][Full Text] [Related]
31. Lack of effect of fluoroquinolone resistance on mortality in subjects with Pseudomonas aeruginosa bacteraemia.
Scheetz MH; Bolon MK; Scarsi KK; Fotis MA; Postelnick MJ
J Infect; 2006 Feb; 52(2):105-10. PubMed ID: 15904961
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia.
Chamot E; Boffi El Amari E; Rohner P; Van Delden C
Antimicrob Agents Chemother; 2003 Sep; 47(9):2756-64. PubMed ID: 12936970
[TBL] [Abstract][Full Text] [Related]
33. Impact of adequate empirical combination therapy on mortality from bacteremic Pseudomonas aeruginosa pneumonia.
Park SY; Park HJ; Moon SM; Park KH; Chong YP; Kim MN; Kim SH; Lee SO; Kim YS; Woo JH; Choi SH
BMC Infect Dis; 2012 Nov; 12():308. PubMed ID: 23157735
[TBL] [Abstract][Full Text] [Related]
34. Pseudomonas aeruginosa bacteremia upon hospital admission: risk factors for mortality and influence of inadequate empirical antimicrobial therapy.
Schechner V; Gottesman T; Schwartz O; Korem M; Maor Y; Rahav G; Karplus R; Lazarovitch T; Braun E; Finkelstein R; Lachish T; Wiener-Well Y; Alon D; Chowers M; Bardenstein R; Zimhony O; Paz A; Potasman I; Giladi M; Schwaber MJ; Klarfeld-Lidji S; Hochman M; Marchaim D; Carmeli Y
Diagn Microbiol Infect Dis; 2011 Sep; 71(1):38-45. PubMed ID: 21763093
[TBL] [Abstract][Full Text] [Related]
35. A five-year review of Pseudomonas aeruginosa bacteremia in children hospitalized at a single center in southern China.
Zhang Q; Smith JC; Zhu Q; Guo Z; MacDonald NE
Int J Infect Dis; 2012 Aug; 16(8):e628-32. PubMed ID: 22709682
[TBL] [Abstract][Full Text] [Related]
36. Risk factors and outcome of Pseudomonas aeruginosa bacteremia among adults visiting the ED.
Lee CC; Lee CH; Hong MY
Am J Emerg Med; 2012 Jul; 30(6):852-60. PubMed ID: 21855263
[TBL] [Abstract][Full Text] [Related]
37. Impact of combination therapy and early de-escalation on outcome of ventilator-associated pneumonia caused by Pseudomonas aeruginosa.
Deconinck L; Meybeck A; Patoz P; Van Grunderbeeck N; Boussekey N; Chiche A; Delannoy PY; Georges H; Leroy O
Infect Dis (Lond); 2017 May; 49(5):396-404. PubMed ID: 28092204
[TBL] [Abstract][Full Text] [Related]
38. Pseudomonas aeruginosa bacteraemia in burns patients: Risk factors and outcomes.
Mahar P; Padiglione AA; Cleland H; Paul E; Hinrichs M; Wasiak J
Burns; 2010 Dec; 36(8):1228-33. PubMed ID: 20965109
[TBL] [Abstract][Full Text] [Related]
39. Active monotherapy and combination therapy for extensively drug-resistant Pseudomonas aeruginosa pneumonia.
Khawcharoenporn T; Chuncharunee A; Maluangnon C; Taweesakulvashra T; Tiamsak P
Int J Antimicrob Agents; 2018 Dec; 52(6):828-834. PubMed ID: 30236956
[TBL] [Abstract][Full Text] [Related]
40. Comparison of mono- and combination antibiotic therapy for the treatment of
Tang SY; Zhang SW; Wu JD; Wu F; Zhang J; Dong JT; Guo P; Zhang DL; Yang JT; Zhang WJ
Exp Ther Med; 2018 Mar; 15(3):2418-2428. PubMed ID: 29456647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
